mesalamine and ajm300

mesalamine has been researched along with ajm300 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Hibi, T; Hirai, F; Ishida, T; Ishiguro, Y; Kajioka, T; Kanke, K; Kishida, S; Kobayashi, K; Matsuoka, K; Miura, Y; Mizusawa, H; Nakajima, K; Ohmori, T; Ohta, A; Watanabe, K; Watanabe, M	1

Trials

1 trial(s) available for mesalamine and ajm300

Article	Year
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The lancet. Gastroenterology & hepatology, 2022, Volume: 7, Issue:7 Topics: Colitis, Ulcerative; Humans; Induction Chemotherapy; Integrin alpha4; Mesalamine; Nasopharyngitis; Phenylalanine; Quinazolinones; Treatment Outcome	2022

Article

Year

AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

The lancet. Gastroenterology & hepatology, 2022, Volume: 7, Issue:7

Topics: Colitis, Ulcerative; Humans; Induction Chemotherapy; Integrin alpha4; Mesalamine; Nasopharyngitis; Phenylalanine; Quinazolinones; Treatment Outcome

2022